Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies.

Abstract

Molecular inhibition of the epidermal growth factor receptor (EGFR) is a promising anticancer strategy and monoclonal antibodies (mAbs) to EGFR are undergoing extensive evaluation in preclinical and clinical trials. EGFR is frequently over expressed in many types of human malignancy and may be associated with prognosis, disease stage and survival. Therefore… (More)

Topics

Cite this paper

@article{Chaudhary2010CardiovascularEO, title={Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies.}, author={Preeti Chaudhary and Ajeet Gajra}, journal={Cardiovascular & hematological agents in medicinal chemistry}, year={2010}, volume={8 3}, pages={156-63} }